- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
The Globe and Mail reported that the United States Supreme Court will hear arguments on Monday regarding the “patentability” of human DNA and remain off-limits to those who have not been granted permission by the patent holder. This legal issue started in 2009 when the American Civil Liberties Union filed a lawsuit against Myriad Genetics Inc., challenging its 7 patents on two human genes related to breast and ovarian cancer. When the federal court ruled the patents invalid, an appeals court overruled the judge’s decision and the case reached the Supreme Court.
The Globe and Mail reported that the United States Supreme Court will hear arguments on Monday regarding the “patentability” of human DNA and remain off-limits to those who have not been granted permission by the patent holder. This legal issue started in 2009 when the American Civil Liberties Union filed a lawsuit against Myriad Genetics Inc., challenging its 7 patents on two human genes related to breast and ovarian cancer. When the federal court ruled the patents invalid, an appeals court overruled the judge’s decision and the case reached the Supreme Court.
As quoted in the market news:
In a 2003 survey, 53 percent of the directors of genetics labs said they had given up some research due to gene-patent concerns. And in 2001, 49 percent of members of the American Society of Human Genetics said their research had to be limited due to gene patents.
Outlook Reports
Featured Stocks
Browse Companies
MARKETS
COMMODITIES
Commodities | |||
---|---|---|---|
Gold | 2192.95 | +20.08 | |
Silver | 24.74 | +0.08 | |
Copper | 4.02 | 0.00 | |
Oil | 82.08 | +0.13 | |
Heating Oil | 2.65 | -0.01 | |
Natural Gas | 1.61 | 0.00 |
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.